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Abstract 
Purpose: To evaluate the expression of leucine zipper transcription factor-like1 (LZTFL1) molecule in 
the gastric cancer tissues, and its relationship to cellular adhesion protein.  
Methods: Expressions of LZTFLl, E-cadherin, β-catenin, intercellular cell adhesion molecule-1(ICAM-1) 
as well as vascular cell adhesion molecule-1 (VCAM-1) in the 133 gastric cancer samples and 40 
gastritis samples were evaluated by immunohistochemistry. Levels of mRNA in gastric cancer and 
latero-cancer tissue were determined by real-time polymerase chain reaction (RT-PCR).  
Results: Protein levels in gastric tissue decreased. The expression of LZTFL1in gastric cancer tissue 
correlated with tumor stage (tumor node metastasis staging), degree of tumor differentiation and 
invasion depth (p < 0.05). Protein expression correlated with E-cadherin positively, and correlated with 
β-catenin and ICAM-1 negatively, but had no correlation with VCAM-1. Compared with tissues remote to 
the cancer, mRNA level of LZTFL1 in gastric cancer decreased significantly. There was no significant 
difference in LZTFL1 mRNA levels in the various clinical pathological tissues. LZTFL1 mRNA 
expression did not correlation with various adhesion factors.  
Conclusion: LZTFL1 is expressed at a low level in gastric cancer tissue. Its protein expression is 
related to cellular adhesion protein, but not to mRNA level. As a suppressor of invasion of cancer cells, 
LZTFL1 may be a potential target for targeted therapy of gastric cancer. 
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It has been reported that gastric cancer (GC) is 
one of the most common malignant tumors [1]. It 
contributes significantly to global cancer death 
[2,3]. Metastasis of GC is a key factor 
responsible for high fatality rate in GC patients 
[4,5]. The aetiology of GC is a complex process 
involving multiple genes. Mutation and loss of 
tumor suppressor gene can promote invasion 
and metastasis of tumors [6].  
 
LZTFL1 is a 299 amino acid-residue tumor 
suppressor molecule of molecular weight 34.6KD 
[7]. It is expressed in low amounts in multiple 
malignant tumors, and is correlated with gastric, 
NSCLC and liver cancers [8,9]. Studies have 
shown that in GC, LZTFL1 is correlated with 
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adhesion factors induced by E-cadherin [8]. 
Research demonstrated that LZTFL1 is 
correlated with Integrin β1 in liver cancer cells. 
Indeed LZTFL1 can participate in invasion and 
metastasis of hepatocellular carcinoma by 
regulating integrin β1 expression. These reports 
show that LZTFL1, as an inhibitory factor of 
cancer cellular invasion and metastasis, probably 
affects migration of cells through cellular 
adhesion protein.  
 
Members of cellular adhesion protein are 
numerous. E-cad is an important member of type 
I in CD family. In adult tissue, E-cad promotes 
inter-adhesion of epithelial cells and maintains 
their integrity and epithelial polarity of their 
organization structure[10]. E-cad inhibits tumor 
occurrence and metastasis. Loss of E-cad CDH1 
in tumor cells increases their potential for 
invasion and metastasis [11]. β–Catenin 
participates in cadherin-mediated inter-cellular 
adhesion, and provides a link between 
extracellular adhesion sites and actin via α-
catenin (α-cat). It is an important cellular 
adhesion molecule, a vital cellular skeletal 
ingredient, and an important component of Wnt 
signal pathway. Abnormalities in intracellular 
location of β-catenin in tumor cells lead to 
decreases in expression of β-catenin envelope, 
thereby reducing inter-cellular adhesion and 
promoting invasion and metastasis [12,13].  
 
ICAM-1, VCAM-1 and CD106 belong to 
immunoglobulin superfamily. ICAM-1 promotes 
inter-adhesion of tumor cells and vascular 
endothelial cells [14]. Thus VCAM-1 participates 
in metastasis of cancer cells as a co-stimulatory 
molecule [15].  
The present study was aimed at investigating the 
correlation between LZTFL1 and different 






All GC and benign gastric disease samples used 
in this study came from patients who underwent 
excision from 2011 to 2014 in Gansu Provincial 
Cancer Hospital, China. The patients were not 
given radiotherapy and chemotherapy before 
tumorectomy. Fresh samples of GC (n = 59) and 
corresponding non-cancerous tissue (taken 5 cm 
distance from cancerous lesions) were excised 
and stored at -80 oC for RNA extraction. 
Relevant clinical data of patients were collected 
from pathological reports and from investigating 
outpatient cases. Features of patients and tumor 
are summarized in Table 1. All patients had 
complete medical records and follow-up data, 
and they signed consent form approved by the 
Hospital’s Ethics Committee (approval certificate 
no. P201108150024). This research was 
conducted according to the Declaration of 
Helsinki promulgated in 1964, as amended in 
1996 [16]. 
 
Immuno-histochemical analyses of samples 
 
Samples were fixed in 10 % formalin and then 
were embedded. Slices of 4μm thickness were 
produced using a microtome. 
 
Table 1: Clinico-pathological features of patients 
 
Clinico-pathologic feature IHC staining  RT-PCR 
Gastric cancer ( %) Gastritis ( %)  Gastric cancer ( %) 
Case no. 133 40  59 
Gender     
Male 98 (74) 20 (50)  44 (75) 
Female 35 (26) 20 (50)  15 (25) 
Age (yr)     
<60 78(59) 27(69)  32(55) 
≥60 55(41) 12(31)  26(45) 
Mean (±SD) 55.85 (±10.63) 52.90 (±13.85)  57.44 (±9.26) 
Tissue differentiation     
Well/moderately 78(68)   37(70) 
Poorly/undifferentiated 37(32)   16(30) 
Clinical stages     
I-II 49(42)   19(37) 
III-IV 69(58)   33(63) 
Lymph node metastasis     
Absent 38(31)   15(27) 
Present 85(69)   40(73) 
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The expressions of VCAM-1, LZTFL1, β-catenin, 
E-cadherin, and ICAM-1 in the clinical samples 
were determined by immuno-histochemical 
staining using SP-9000 Histostain TM Plus kits 
(ZYMED, South San Francisco, USA). The 
concentration of the first antibody was 3µg/ml. 
Negative control was PBS, which substituted for 
the first antibody. 
 
The immuno-histochemical scores were given by 
two independent pathologists naïve to the clinical 
information on the samples scored. Score 
standards were measured by Sinicrope [12]. 
Positive results were based on percentage of 
staining multiplied by positive cells (≥ 4 positive, 
< 4 negative). Intensity of staining was scored as 
follows: (d) 0 = no staining (c) 1 = light; (b) 2 = 
moderate staining; and (a) 3 = strong staining. 
Percentage scores for positive cells were graded 
as follows: (e) < 5  % = 0; (d) 5 - 25 % = 1; (c) 25 
- 50 % = 2; (b) 50 - 75 % = 3; and (a) > 75 % = 4.  
 
Fluorescent quantitative measurement of 
total RNA 
 
Total tissue RNA was extracted through Trizol 
reagent (Takara Biotechnology, China). Its 
concentration and purity were determined 
spectrophotometrically. RNA was transformed 
into cDNA using PrimeScriptTM RT kits (Takara 
Biotechnology, Dalian, China). RNA addition and 
system configuration followed assay kit 
requirements. Premix Ex TaqTM II kits (Takara 
Biotechnology, Dalian, China) were used for real-
time PCR to measure mRNA expression. The 
experimental procedures were in line with 
instructions in the assay kits. GAPDH was used 
as internal reference. Relative gene expression 
was calculated by 2-△△Ct method. The primers 




All real-time data were collected and presented 
as Mean ± SD. Data were analyzed with ANOVA 
or t-test as appropriate. Calculation and analyses 
were done using IBM SPSS 19.0. Differences 
between LZTFL1 and clinical pathological 
features of GC were analyzed using chi-square 
test. Correlations between LZTFL1 and 
expressions of E-cadherin，β-catenin，VCAM-1 
and VCAM-1were analyzed through Spearman’s 
rank correlation coefficient. P < 0.05 was taken 






catenin and protein expression in clinical 
samples  
 
The levels of VCAM-1, LZTFL1，β-catenin, E-
cadherin and ICAM-1 of 133 gastric cancer 
tissues embedded in paraffin, and 40 gastritis 
tissue samples were measured by immuno-
histochemical staining. The results showed that 
the expressions of LZTFL1, β-catenin and E-
cadherin in GC tissue were lower than those in 
gastritis tissue (p < 0.05). The expression of 
VCAM-1 (p < 0.05) was much higher. There was 
no significant difference in the expressions of 
VCAM-1 between GC tissue and gastritis tissue 
(Table 3). Some typical cases are shown in 
Figure 1.  
 
Table 2: Primer series of relevant genes 
 
Gene Upstream primer5’-3’ Downstream primer 5’-3’ 
LZTFL1 ATTGGAGCATAGGGCTTGTTGT AAGGGCACAGAAACTGGTAAGTG 
E-cadherin GAGTGCCAACTGGACCATTCAGTA AGTCACCCACCTCTAAGGCCATC 
ICAM-1 TGTATGAACTGAGCAATGTGCAAGA CACCTGGCAGCGTAGGGTAA 
VCAM-1 GGCGCCTATACCATCCGAAA AGAGCACGAGAAGCTCAGGAGAA 
β-catenin TGGCACCCAGCACAATGAA CTAAGTCATAGTCCGCCTAGAAGCA 
GAPDH TGTATGAACTGAGTGTGCAAGA CACCTGGCAGCGTAGTAA 
 
Table 3: Expressions of LZTFL1, E-cadherin, β-catenin, ICAM-1 and VCAM-1 in clinical samples 
 
Protein 
Gastric cancer  Gastritis  
N Positive PR ( %)  N Positive PR ( %) P-value 
LZTFL1 133 49 37  40 26 65 ** 
β-catenin 128 73 57  37 30 81 ** 
E-CD 130 35 27  39 28 72 ** 
ICAM-1 128 99 77  38 27 71 0.42 
VCAM-1 133 57 43  40 10 25 * 
Note: *P ＜ 0.05，** p ＜ 0.01. PR = positive rate 
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Figure 1: IHC analysis of the expression of 
LZTFL1, β-catenin, E-cadherin, ICAM-1 and 
VCAM-1 (X 200). Note: The expressions of 
LZTFL1 in gastric carcinoma tissues were low (a) 
and highly expressed in the gastritis tissues (b). 
The expressions of β-catenin in the gastric 
cancer tissues (c) was ectopic (pulp / nuclear) or 
not (d); E-cadherin was not expressed in gastritis 
tissues (f)，but not in gastritis tissues gastric 
cancer tissues, and was highly expressed; ICAM-
1 was expressed highly in the gastric carcinoma 
(g) and locally expressed in gastritis tissues (h); 
VCAM-1 was highly expressed in the gastric 
cancer tissues (i) and low / non-expressed in 
gastritis tissues (j) 
 
Correlation between LZTFL1, E-cadherin, β-
catenin, ICAM-1 and VCAM-1 and pathologi-
cal features of gastric cancer patients  
 
LZTFL1 expression in GC tissue was positively 
correlated with tumor stage and degree of tumor 
differentiation (p < 0.05), volume of tumor 
primary site and size of affected adjacent tissue 
(p < 0.01). However, it was not with tumor size (p 
> 0.05). There were no significant differences in 
LZTFL1 between GC–with-lymph metastasis 
group and non-metastasis group (p > 0.05). 
There were  also no significant differences in age 
and sex of the GC patients. Β-catenin expression 
in well-differentiated GC tissue was higher than 
in low-differentiated or undifferentiated tissue (p 
< 0.05). E-cadherin expression rate decreased 
along with increase in tumor stage (TNM 
staging). 
 
Expression of E-cadherin in well-differentiated 
GC group was higher than in low differentiated or 
undifferentiated tissue (p < 0.05), but its 
expression in GC–with-lymph-metastasis group 
was significantly lower than that in the non-
metastasis group (p < 0.05). ICAM-1 and VCAM-
1 expressions in GC patients with lymph 
metastasis were significantly higher than 
corresponding values in non-metastasis group (p 
< 0.05), but there were no significant differences 
in the other groups (p > 0.05). 
 
LZTFL1, E-cadherin, β-catenin, ICAM-1 and 
VCAM-1 mRNA expression in clinical samples  
 
Levels of mRNAs of LZTFL1, E-cadherin, β-
catenin, ICAM-1 and VCAM-1 in 59 fresh GC 
tissues and their corresponding non-cancerous 
tissues were determined by qRT-PCR. The 
results showed that mRNA levels of LZTFL1, E-
cadherin in GC tissue were significantly 
decreased when compared with corresponding 
paired, non-cancerous tissue. There were no 
significant differences in mRNA expression levels 
of β-catenin, ICAM-1 and VCAM-1 mRNA 
(Figure 2). In addition, there were no significant 
differences in LZTFL1 mRNA expression among 
different groups with clinical/pathological features 
(p > 0.05, Table 5). 
 
Correlation between LZTFL1 and adhesion 
factors  
 
The results of correlation analysis showed that 
LZTFL1 protein expression was positively 
correlated with E-cadherin, and negatively 
correlated with β-catenin and ICAM-1. 
Expression of LZTFL1 mRNA had no correlation 
with various adhesion molecules. The results of 
correlation analysis between LZTFL1 and various 




The results obtained in this study showed that 
LZTFL1 in epithelial cells of normal tissues was 
highly expressed, but was lowly expressed in 
samples of corresponding invasive cancer group 
[7]. LZTFL1 expression is of prognostic 
significance in GC. In vitro studies have shown 
that the expression of LZTFL1 in tumor tissue 
can inhibit metastasis of tumor cells [8]. 
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Table 4: Expressions of LZTFL1, E-cadherin, β-catenin, ICAM-1 and VCAM-1 protein and clinic-
pathological parameters in GC tissues 
 
 LZTFL1 Β-catenin E-CD ICAM-1 VCAM-1 
Variable PR p PR p PR p PR p PR p 
Gender           
Male 40/99  65/100  30/104  83/104  45/106  
Female 9/27 0.50 18/27 0.87 5/26 0.32 16/24 0.17 11/27 0.87 
Age (years)           
<60 31/74  48/73  18/76  59/75  33/78  
≥60 18/52 0.41 35/54 0.91 17/54 0.32 40/53 0.67 23/55 0.96 
Clinical stages           
I- II 22/47  32/47  16/48  35/46  24/49  
III –IV 19/67 * 37/67 0.17 11/67 * 45/68 0.26 27/69 0.28 
Tissue 
differentiation           
Well 4/6  4/6  4/6  3/6  3/6  
Moderate 42/74  50/74  19/73  51/73  30/75  
Poor/ 
undifferentiated 13/35 * 14/34 * 5/34 * 28/33 0.08 18/35 0.29 
Lymphatic 
metastasis           
No 17/36  25/35  12/38  21/37  12/38  
Yes 28/83 0.16 51/84 0.27 11/82 * 62/83 * 42/82 * 
Depth of invasion           
T1-2 3/27  17/27  9/28  16/24  9/27  
T3-4 35/86 ** 59/86 0.59 18/86 0.23 68/89 0.33 41/89 0.24 
tumor size           
<5cm 21/53  40/53  8/52  40/51  29/54  
≥5cm 6/24 0.21 16/24 0.42 6/23 0.27 13/23 0.05 8/24 0.10 





Figure 2: Expression of mRNA in adjacent non-cancerous tissues and in paired GC tissues by Real-
time PCR. *p > 0.05 (paired Student t-test) 
 
LZTFL1      E-cadherin   β-catenin       ICAM-1         VCAM-1 
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Table 5: Expression of LZTFL1 transcripts and correlation between LZTFL1 and clinic-pathological 
parameters in GC tissues 
 
Variable LZTFL1 P-value T/N > 2 T/N 2-0.5 T/N < 0.5 
Age (years)     
<60 9 6 17 0.627 ≥60 5 4 17 
Gender     
Male 8 7 28 0.183 Female 6 3 6 
Tumor size (cm)    
＜5cm 6 7 22 0.524 ≥5cm 5 2 10 
Tissue differentiation    
Well 3 2 8 
0.614 Moderate 5 6 12 
Poor/undifferentiated 4 1 11 
Depth of invasion    
T1+T2 2 3 8 0.638 T3+T4 9 5 23 
Lymph node metastasis    
No 3 3 8 0.886 Yes 11 7 22 
TNM staging     
I+II 2 2 15 0.174 III+IV 9 6 17 
 
    Table 6: Correlation between expressions of LZTL1 and adhesion molecules in IHC and PCR 
 
Variable IHC  PCR 
 R P-value  R P-value 
β-catenin -0.24 **  -0.02 0.87 
E-cadherin 0.17 **  0.20 0.14 
ICAM-1 -0.12 **  -0.04 0.77 
VCAM-1 -0.01 0.78  -0.03 0.82 
     Note: ** p＜0.01 
 
Indeed, the decreased expression of LZTFL1 
was correlated with low survival rate of non-small 
cell lung cancer (NSCLC) and recurrence [17]. 
Kaplan–Meier analysis showed that high 
expression of LZTFL1 led to longer survival 
terms than low expression of LZTFL1 in GC 
patients [8]. 
 
In this study the expression of LZTFL1 protein in 
GC tissue was lower than that in gastritis tissue, 
and the expression of LZTFL1 protein in GC 
tissue was significantly correlated with tumor 
stage and degree of tumor differentiation. Higher 
degrees of tumor differentiation were associated 
with higher expressions of LZTFL1. Thus 
LZTFL1 protein tended to decline as GC 
worsened.  
 
It was also found that LZTFL1 expression 
increased with increases in extent of 
invasiveness. This finding is at variance with 
those of Wang et al [8] who reported that LZTFL1 
suppressed gastric cancer cell migration and 
invasion. This disparity may be due to sample 
origin and sample number, and merits further 
investigations.  
 
The expression levels of LZTFL1 mRNA in the 
GC patients were lower than in corresponding 
peri-carcinogenous tissue. In addition, there were 
no obvious differences in expression levels of 
LZTFL1 mRNA amongst GC groups with 
different clinical and pathological features. These 
results suggest that the processing and 
modification steps after LZTFL1 gene 
transcription may influence LZTFL1 protein 
expression level.  
 
With the aid of laser-scanning confocal 
microscope, Wei has reported that LZTFL1 and 
E-cadherin have co-localization features in 
intestinal epithelial cells with normal 
differentiation, implying that LZTFL1 may 
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stabilize adhesion connection induced by E-
cadherin [6]. Wang et al have suggested that 
cytoplasmic LZTFL1 and E-cadherin inhibit β-
catenin nuclear transport and EMT processes in 
GC cells, thereby inhibiting their invasion and 
metastasis[7]. This is in agreement with the 
results obtained in the present study, in which 
LZTFL1 protein expression was positively 
correlated with E-cadherin, and negatively 
correlated with β-catenin.  
 
It has been reported that LZTFL1 can regulate T-
cell activation and IL-5 levels[18]. The co-
stimulatory signal of T-cell activation process 
emanates from adhesion effects between the co-
stimulatory signal of T-cell and ligand of antigen-
presenting cells. ICAM-1/LFA-1 is one of them 
[19]. VCAM-1 is located on the surface of various 
cells. It participates in metastasis of tumor cells 
as a co-stimulatory molecule. Therefore, the 
present study also investigated correlations 
between LZTFL1, ICAM-1 and VCAM-1. The 
results showed that LZTFL1 was negatively 





The results obtained in this study demonstrate 
that LZTFL1 is expressed at low levels in GC, 
and its expression level decreases with 
progression of GC. The results also indicate that 
LZTFL1–induced inhibition of cancer involves the 
participation of some adhesion proteins. As a 
suppressor of invasion of cancer cells, LZTFL1 
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